Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionPlace of product in therapyDisease description

Diagnosis

2 evidence topics · 3 sources

Diagnostic genetic testing of the epilepsies

“We emphasize the importance of genetic testing for individuals with epilepsy” (opens the source at this quote in a new tab)

SCN8A molecular diagnosis

“a heterozygous pathogenic (or likely pathogenic) variant in SCN8A” (opens the source at this quote in a new tab)